Objective: Hostile proximal aortic neck (HN) challenges the suitability for standard endovascular aneurysm repair (EVAR) of patients at high risk for "open" repair. However, there has been little if any focus placed on the individual role of the "nonlength" HN features in EVAR outcomes. The aim of this study was to evaluate their individual and potentially predictive role in outcomes of EVAR under HN conditions. Methods: Data of 156 consecutive EVAR patients with short (<15 mm) HN, treated with the Endurant device (Medtronic Cardiovascular, Santa Rosa, Calif) at three European academic vascular centers between 2007 and 2015, were collected and retrospectively analyzed. All patients had at least one of the four well-known nonlength HN criteria (width >32 mm or bulge, angulation >60 degrees, reverse taper anatomy, and circumferential thrombus or calcification >50%) and underwent standard EVAR without additional techniques, such as use of chimney grafts or endoanchors. Primary end points were absence of type IA endoleak at 1 month and midterm follow-up and aneurysm sac stabilization or shrinkage. Secondary end points were 30-day mortality, overall survival, and secondary interventions related to EVAR. The study cohort was classified in two subgroups related to neck length (length <10 mm and length between 10 and 14 mm) as well as in two subgroups according to on-label or off-label stent graft use.
Results: Mean clinical and radiologic follow-up was 41.1 6 24.7 and 31.7 6 19.0 months, respectively. Overall EVAR-related mortality was 1.9% (n ¼ 3). The total type IA endoleak rate was 5.8% (n ¼ 9). In four patients, the type IA endoleak was detected intraoperatively and solved by endovascular means. A type IA endoleak was detected in three patients at 1 month and in two patients at 2-year follow-up. During follow-up, five patients showed an increase of aneurysm diameter due to type II endoleak and were treated by secondary endovascular reinterventions. The total number of all EVARrelated secondary procedures in the midterm was 12 (7.7%). Univariate analysis showed that the center of treatment and the clinical or anatomic features were not associated with adverse outcomes. Multiple regression and Cox regression analysis of HN features revealed that reverse taper anatomy (conical neck) was the single and significantly associated predictor of proximal EVAR failure (P < .012). Width >32 mm, angulation >60 degrees, and calcification or thrombus were not associated with adverse outcomes. Analysis between HN length cohorts and between on-label and off-label subgroups revealed no difference in outcomes.
Conclusions: A conical neck in hostile anatomies represents the single strongest factor associated with proximal failure of standard EVAR. This finding should be considered and highlighted apart from the length of the infrarenal neck to prevent midterm failure of standard EVAR. (J Vasc Surg 2017; 66:1686-95.) Endovascular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAAs) was introduced by Parodi in 1991. 1 Long-term outcomes and benefits of EVAR in comparison with the traditional "open" AAA repair are controversial. 2, 3 Currently, the low perioperative incidence of major adverse events after EVAR justifies its use in patients at high risk for open repair with suitable anatomic criteria. 4 Infrarenal hostile proximal aortic neck (HN) represents the most common reason for exclusion of patients from EVAR because of unsuitable anatomy. 5, 6 Unsuitable proximal aortic neck, which is associated with a significantly higher incidence of type IA endoleak and reinterventions, is based on the presence of aortic neck length #15 mm and one or more of the following four criteria: infrarenal angle >60 degrees, circumferential thrombus with >2-mm thickness or circumferential calcification >50%, reverse taper anatomy (gradual neck dilation >2 mm), and diameter >32 mm or neck bulge. [7] [8] [9] However, except for neck length, the individual contribution of each one of the four coexistent unsuitable neck features to worse EVAR outcomes has not yet been evaluated. It remains unknown if all of these four "theoretically unsuitable" characteristics play an equal role and have the same impact on potential proximal failure of EVAR. The aim of this study was to evaluate their individual predictive role in EVAR outcomes using a single and lastgeneration stent graft with suprarenal fixation (Endurant; Medtronic Cardiovascular, Santa Rosa, Calif) in AAA patients with short neck and HN features.
METHODS
Population of patients and study design. This is a retrospective study with prospectively collected data from three European academic vascular centers. The study period was 2007 to 2015, and the study comprises 161 consecutive patients with short (<15 mm) HN who received implantation of the Endurant endograft for treatment of nonruptured AAA. The study was conducted in compliance with the principles of the Declaration of Helsinki, and the local Ethical Committees approved the protocol. All included patients signed an informed consent document before endograft implantation and especially regarding the on-label or off-label use.
For this report, we followed the recommendations of the Ad Hoc Committee for reporting standards of EVAR. 10 Inclusion criteria included the presence of short (range, 8-14 mm) proximal aortic neck and concomitant existence of one or more of the following four HN features: infrarenal angle >60 degrees, circumferential thrombus with >2-mm thickness or circumferential calcification >50%, reverse taper anatomy (gradual neck dilation >2 mm), and diameter >32 mm or neck bulge resulting in neck width >32 mm. Furthermore, using the manufacturer's instructions for use (IFU) for Endurant, the patients were classified in two groups: those with short neck but still within the IFU (group 1, on-label) and those outside the IFU (group 2, off-label).
In addition, to analyze in-depth the potential correlative influence on outcomes of proximal aortic neck length with the concomitant HN features, we divided the patients into two cohorts; cohort 1 with neck length <10 mm and cohort 2 with neck length between 10 and 14 mm.
EVAR procedure. Data on anatomy were obtained preoperatively and postoperatively from a picture archiving and communication system using dedicated three-dimensional (3D) computed tomography angiography (CTA) analysis software and the central lumen line analysis. 11 The picture archiving and communication system data from each center were sent on hard drives to the other two centers, and all measurements were made blindly by two seasoned EVAR surgeons with a personal experience of >100 cases. For data analysis, we used the mean values of these two blind measurements. We measured the proximal aortic neck diameter, outer wall to outer wall, just below the lower renal artery and, as the proximal neck length was recorded, the distance from the lower renal artery to the point of the aneurysm's formation. The infrarenal neck angle was measured between the aortic neck and the longitudinal axis of the AAA as it was seen on 3D CTA images. The maximum AAA diameter was also measured from outer wall to outer wall perpendicular to the central lumen line. All Endurant endografts were implanted in an operational theater equipped with a conventional C-arm at center 1 (Stenoscop; GE Healthcare, Wauwatosa, Wisc) and center 2 (Pulsera; Philips Healthcare, Best, The Netherlands) and an angiography suite (Artis zeego; Siemens Healthcare, Hoffman Estates, Ill) at center 3. Centers 1 and 2 used common femoral artery cutdowns for endovascular access; center 3 used the percutaneous access technique in most patients with the Perclose Prostar system (Abbott Vascular, Abbott Park, Ill). In all cases, the standard treatment protocol included the stent graft's balloon dilation at the proximal neck with a Reliant AB46 (Medtronic). In cases with high risk for type IA endoleak or with intraoperative detection of type IA endoleak, the operator performed any preventive or therapeutic adjunctive proximal neck procedure to avoid or to seal the Ia endoleak successfully before completion angiography. Similarly, if it was considered necessary, the operator performed any adjunctive iliac or peripheral procedure to ensure the long-term patency of the implanted stent graft.
In five cases of center 3, a preventive proximal fixation of the stent graft using the Aptus system (Medtronic) was considered necessary to minimize the possibility of postoperative type IA endoleak. In fact, these five patients did not experience type IA endoleak for the entire follow-up period. To avoid bias in the analysis of results, these five patients were excluded, and the final total number of patients included in analysis was 156. Center 1 and center Definitions. Technical success was defined as primary, assisted primary, and secondary. Primary technical success resulted from a successfully completed endovascular procedure without type I or type III endoleak and with patency of both renal arteries, both stent graft limbs, and the peripheral vasculature within the first 24 hours postoperatively. Primary assisted technical success described the requirement for an unplanned additional endovascular procedure; secondary technical success occurred when an unplanned additional open surgical procedure took place. Migration was determined by measuring the distance from the lower renal artery to the most cephalad point of the covered part of the stent graft on 3D CTA images. Migration was suspected if follow-up CTA showed a displacement $2 mm compared with the previous studies. Similarly, AAA sac expansion and shrinkage were defined as $2-mm increase or decrease, respectively, of the maximum sac diameter; all AAAs with #2-mm differences in diameter were considered stable.
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Surveillance protocol. CTA, peripheral artery duplex ultrasound, and plain radiography of the device in two projections were performed before hospital discharge, at 1 year, and yearly thereafter until the patient reached at least the fifth postoperative year. In addition, nonscheduled CTA was performed only in cases of postoperative events and complications. During follow-up, in patients with chronic renal failure, the detection of any clinically severe endoleak was based on the aneurysm's diameter measurement on CTA without contrast medium combined with color duplex ultrasound. Using contrastenhanced CTA, endoleak was determined if extravasation of contrast material was present in the space between the prosthesis and the aneurysm wall. In cases of chronic renal failure, endoleak was recorded if the flow and spectral signal were detected outside the prosthesis on color duplex ultrasound. Diagnosis of endotension was per protocol considered type IA endoleak.
End points. Primary end points were the absence of type IA endoleak at 1 month and midterm follow-up and aneurysm sac stabilization or shrinkage. Secondary end points included 30-day mortality, overall survival, and any EVAR-related complication or secondary intervention for the entire follow-up period. More specifically, data regarding the observed type IA endoleaks, all other types of endoleak, stent graft migrations, stent fatigue fractures, limb thrombosis, endovascular or open reinterventions, aneurysm sac diameters, AAA rupture, and mortality were recorded and analyzed.
Statistical analysis. Categorical variables are presented as counts and percentages. Continuous variables are presented as mean 6 standard deviation if the data are normally distributed or median (range) if the data are skewed. Continuous variables were compared with nonparametric Wilcoxon signed rank test, and comparisons between nominal data were made by Pearson c 2 test as appropriate. Identification of preoperative anatomic proximal aortic neck features or clinical factors with a potential predictive role in adverse outcomes was based on multiple logistic regression analysis, and assessment of the four non-neck length HN features in prediction of adverse outcomes was based on a Cox regression predictive model. Estimation of primary and secondary end point rates at 3 years postoperatively was performed by Kaplan-Meier life-table analysis. Subgroup analysis for on-label and off-label use as well as for use in the two proximal aortic neck length cohorts was also performed. Data were collected and analyzed using SPSS 23.0 Statistics (IBM Corp, Armonk, NY). Significance for all performed statistical tests was set at the level of P < .05.
RESULTS
The mean age of the 156 included patients was 73.4 6 8.6 years, and 145 (92.9%) of them were male. All patients were at high risk for open repair (American Society of Anesthesiologists class 3 or 4). Demographics, preoperative aneurysm characteristics, and operative data are described in Table I . The mean maximum AAA diameter was 62.2 6 10.1 mm, and 34 (21.8%) of them were symptomatic. The mean proximal aortic neck length was 11.8 6 1.8 mm (range, 8-14 mm), and 31 patients (19.9%) presented with proximal neck length <10 mm. In 22 (14.1%) and 87 (55.8%) patients, one and two additional coexistent nonlength HN features, respectively, were recorded, whereas 47 (30.1%) patients fulfilled three or four coexistent HN criteria. In 73 patients (46.8%), use was classified as off-label, and 22 of them met two and three "out of IFU" criteria (n ¼ 18%-11.5% and n ¼ 4%-2.6%, respectively). The mean oversizing of stent grafts at the proximal aortic neck was 22.9% 6 7.3% (range, 9.1%-33.3%). Table II Operative results. A persistent intraoperative type IA endoleak was detected in four (2.5%) cases, and all of them were successfully excluded before the procedure's completiondin 2 cases with a proximal cuff placement, in 1 case using a Palmaz XL stent (Cordis, Bridgewater, NJ), and in 1 patient with coil embolization. In addition, during the primary EVAR procedure, we performed an adjunctive iliac limb or native artery stent angioplasty in 18 (11.2%) patients to ensure long-term patency; in four (2.5%) cases, we occluded a concomitant internal iliac aneurysm with an Amplatzer Plug (St. Jude Medical, St. Paul, Minn; n ¼ 3) or coil embolization (n ¼ 1). The total number of intraoperative adjunctive procedures that were considered necessary to ensure successful EVAR was 26 (16.7%; Table I ). The primary technical success rate was 83.3% (n ¼ 130), whereas the primary assisted technical success rate was 100%. In five (3.1%) cases, we implanted a scheduled aortouni-iliac endograft with a femorofemoral crossover bypass because of chronic preoperative unilateral iliac occlusion.
First-month results. The 30-day mortality rate was 1.9% (n ¼ 3). All three patients died of acute myocardial infarction. Thirty-day morbidity was observed in 14 patients (9.0%) and included 1 access (femoral) artery dissection, 1 groin infection, and 12 cases of mild postimplantation syndrome. Thirty-day type IA endoleak rate was 1.9% (n ¼ 3). Two patients were successfully treated with secondary intervention by endovascular means (proximal cuff placement). The third patient was diagnosed with cancer that was known at the time of EVAR treatment. Following a multidisciplinary approach and because of his poor clinical condition and prognosis, the endoleak was considered not immediately lifethreatening, and conservative treatment with close follow-up was preferred. The patient died at the fourth postoperative month of his underlying disease with no signs of rupture.
Midterm and overall results. There was no mortality related to EVAR procedures in the midterm. The overall mortality rate of the series was 21.2% (n ¼ 33, including the three 30-day and EVAR-related deaths; Fig 1) . The main causes of death included coronary (n ¼ 14), oncologic (n ¼ 7), and respiratory (n ¼ 3) diseases. In addition, six patients died of renal disease, stroke, and multiorgan failure (n ¼ 2 for each cause). Proximal migration of the stent graft and endotension were not detected in any of our cases for the entire follow-up period. Midterm type IA endoleak was detected in two (1.3%) patients, in both cases at 2 years of follow-up. These two patients were successfully treated by elective implantation of a Palmaz XL stent.
The total number of type IA endoleak cases (intraoperative, first month, and midterm) was nine (5.8%). During follow-up, type II endoleak was detected in 39 (25.0%) patients at a mean time interval of 6.8 6 12.1 months (range, 1-41 months) from EVAR. In 34 (87.2%) of them, the endoleak was solved spontaneously, and the aneurysm's size remained stable. Five patients with type II endoleak and evidence of increased AAA diameter required secondary lumbar artery coil and Onyx (ev3, Covidien, Plymouth, Minn) embolization. Additional EVAR-related secondary procedures included one patient with femoral access dissection at 1 month and two patients with stent graft limb occlusion occurring at the midterm. The total number of all EVAR-related secondary procedures was 12 (7.7%). The cumulative freedom from all EVAR-related secondary procedures at 3 years was 92.3% (Fig 3) . The non-EVARrelated secondary procedures for the entire follow-up period were five (3.2%) and included treatment of proximal thoracic aorta disease (n ¼ 2), peripheral arterial atherosclerotic disease (n ¼ 1), and renal angioplasty (n ¼ 2).
The mean preoperative maximum AAA diameter in 153 patients (excluding 3 patients with early death) was 62.1 6 11.0 mm (range, 42-99 mm). The relevant postoperative diameter was 56.9 6 13.2 mm (range, 30-99 mm). The sac regression was significant with P < .001. In 58 (37.9%) patients, the AAA remained stable; in 90 (58.8%) patients, the sac decreased in diameter (mean The relevant preoperative data were 62.1 6 11.0 mm (range, 42-99 mm). The difference between preoperative and postoperative maximum AAA diameter was significant (nonparametric Wilcoxon signed rank test, P < .001).
b
In 153 patients who survived beyond the first month of follow-up. c Data presented as median and range because of the small number of patients with increased diameter. decrease of 9.0 mm); and in 5 (3.3%) patients, the sac increased (median increase of 3 mm). The reason for sac increase in these five cases was a type II endoleak, and these patients required an endovascular reintervention (Table II) , with no further evidence of continued type II endoleak. Table III summarizes the univariate assessment of the effect of HN features or clinical conditions on incidence of all type IA endoleaks (n ¼ 9) and all EVAR-related reinterventions (n ¼ 12). Analysis showed that none of the studied parameters, including the coexistent HN features, off-label use, proximal neck length <10 mm, and treatment center, was significantly associated with EVAR-related reinterventions. Similarly, not significant differences were recorded in analysis of type IA endoleaks with one significant exception, the presence of reverse taper anatomy of the proximal aortic neck. The incidence of type IA endoleak in this cohort of patients (n ¼ 46) was 13.0% (n ¼ 6) compared with 2.7% (n ¼ 3) in patients with cylindrical neck (P ¼ .012; Table III) .
Multiple regression analysis (Table IV) was performed to identify factors with potential influence in four parameters of outcomes: total type IA endoleaks (n ¼ 9), all EVAR-related reinterventions (n ¼ 12), total EVARrelated mortality (n ¼ 3), and 30-day morbidity (n ¼ 14). We entered into the equation five potentially predictive factors of adverse outcomes: (1) EVAR out of IFU, (2) proximal aortic neck length <10 mm, (3) center of treatment, (4) EVAR in a symptomatic patient, and (5) number of coexistent nonlength HN features. Analysis showed that none of these five factors was significantly associated with adverse outcomes.
The primary goal of our study was to explore the individual predictive role of the four nonlength HN features on the incidence of all type IA endoleaks and all EVARrelated secondary procedures in patients with short proximal aortic neck. To investigate this, we performed Cox regression analysis (Table V) , which showed that none of the four studied nonlength HN features was a significant predictor of EVAR-related reinterventions. Conversely, the reverse taper anatomy increased the hazard 6.7 times and was a strong (P ¼ .010) predictor of type IA endoleaks. At the same test, neck diameter >32 mm (ie, 33 mm) showed a trend in prediction of type IA endoleaks (hazard ratio, 3.748); however, this association did not reach statistically significant levels (P ¼ .220). Infrarenal neck angulation >60 degrees and circumferential thrombus or calcification were not associated with adverse outcomes at all (P ¼ .956 and P ¼ .958, respectively).
DISCUSSION
Worldwide performance of EVAR has surpassed 20 years, resulting in greater experience of physicians and development of better "last"-generation stent grafts that allow the treatment of patients with challenging anatomy and especially under HN conditions. Besides that, complications of open repair in this setting are not unusual and can be an important issue, requiring special and highly skilled techniques to deal with them. 12 These facts push the indications for EVAR further in patients at high risk for open repair of AAA, even for cases that fall outside the current IFU standards. Our results showed that in general, even under extremely hostile aortic neck conditions, EVAR with a third-generation and suprarenal fixation endograft was safe and successful. The total number of type IA endoleak cases was nine (5.8%), but it is notable that four of them were detected and solved successfully intraoperatively. During follow-up, freedom from postoperative type IA endoleaks and of EVAR-related reinterventions was as high as 96.8% and 92.3%, respectively. These results were not affected by the treatment center and are similar to the previously reported outcomes of contemporary large series in the nonhostile neck EVAR population. 13, 14 In a recent work by AbuRahma et al 8 as well as in similar previous studies, 5,7 the authors reported a nearly fourfold increase in the risk for development of a type IA endoleak and a twofold increase of perioperative complications in patients treated by EVAR with hostile neck anatomy. Subsequently, they concluded that there is an ongoing uncertainty about the outcomes of EVAR out of IFU. Their data included 526 patients who were treated by seven different endografts. Furthermore, 289 patients were treated by an infrarenal fixation stent graft, 74 patients with a first-generation device that is no longer available in Europe; only 8 patients were treated with an Endurant device, which represents a typical last-generation endograft with suprarenal fixation. In our practice, the off-label use of Endurant resulted in only a 2.6% incidence of type IA endoleak compared with 3.2% in the on-label use, and our results for the required secondary procedures were similar (2.6% vs 5.1%, respectively). The study by Leurs et al 15 as well as a recent meta-analysis by Antoniou et al 16 showed results similar to those of AbuRahma et al, 8 and all these studies shared the same limitation of comparing several different and potentially inappropriate endografts for performing EVAR in hostile neck conditions. In recognition of this situation and despite their analysis, Antoniou et al 16 concluded, "Insufficient high-level evidence for or against performing standard EVAR in patients with hostile neck anatomy exists" and "EVAR should be cautiously used in patients with anatomic neck constraints." Regarding the cross-adverse effects of concomitant nonlength HN features, we observed that the coexistence of reverse taper anatomy was a strong predictor of type IA endoleak, increasing the relative risk 6.7 times (P ¼ .10). This evidence highlights that the presence of reverse taper anatomy probably further diminishes the available proximal landing zone. In our study, the criterion for definition of reverse taper anatomy was the gradual neck diameter increase by 2 mm, and we believe that under these circumstances, conventional EVAR is better avoided. Although it did not reach significant levels (P ¼ .220), the presence of very wide neck (diameter of 33 mm) also increased the possibility for type IA endoleak 3.7 times. We suppose that analysis in a greater sample of patients with short neck might reveal that neck width >32 mm is also associated with proximal EVAR failure, and this practice should also be avoided, particularly in young patients with long life expectancy. Surprisingly, coexistent infrarenal neck angle >60 degrees and circumferential thrombus or calcification were not associated with adverse outcomes at all, and this might reflect the high conformability of this particular endograft, which allows a better wall apposition of the stent graft in short and angulated proximal aortic necks.
In performing EVAR in patients with a short neck, an important issue is the possibility of increased incidence of primary adjunctive procedures to seal the hostile aortic neck with the increased cost. In this condition, the available options are mainly proximal aortic extension, balloon-expandable stents, and endostaples. Proximal aortic extension might be necessary only in cases with inadequate deployment of the primary endograft in an already short aortic neck; however, this situation can obviously be avoided in the setting of an experienced vascular center. In our series, it was necessary to implant only two proximal extensions. We also used a balloon-expandable stent in one case and coil embolization in another one. The total incidence of primary adjunctive procedures related to sealing of the aortic neck was 2.6%. We consider this a low rate in performing EVAR under hostile neck conditions, and our outcomes fully advocate the extra cost of primary adjunctive procedures. We also performed a significant number (n ¼ 22 [14.1%]) of primary adjunctive procedures to ensure patency of the endograft limbs and peripheral vasculature or to exclude internal iliac aneurysm. Our policy of preventive primary adjunctive procedures resulted in the observed very low (n ¼ 2 [1.3%]) incidence of stent graft limb thrombosis at midterm and subsequently in the low incidence of reinterventions during follow-up. We believe that one should make every effort to use any available means during primary EVAR to avoid the undesirable reinterventions and to achieve the best long-term results. This "preventive action" might result also in better quality of life for patients as well as avoidance of significantly higher cost for the secondary procedures.
Another point of criticism for EVAR in this situation is that currently, different techniques are available to deal with the problem of hostile aortic neck; the fenestrated, branched, and chimney EVAR techniques show remarkable results. 6, 17 However, it is also true that these techniques and especially the fenestrated and branched techniques are more technically demanding and require better imaging equipment. In addition, they incur significantly higher costs and time delay of treatment compared with standard EVAR, limiting their use to only some centers of expertise. Our study showed that in the absence of reverse taper anatomy, an aortic neck of at least 8 mm provides adequate proximal landing zone for a secure EVAR using the Endurant endograft and probably with any similar third-generation endograft with suprarenal fixation. Although the on-label vs off-label use of these endografts has been reported, 18 the individual role of reverse taper anatomy in EVAR cases with short proximal aortic neck has not yet been evaluated. Previous studies on this topic assessed the reverse taper anatomy in a greater mean length (33 6 10 mm) of proximal aortic neck or focused exclusively on the impact of proximal neck angulation. 19, 20 In design and accomplishment of this study, we made every effort to minimize the bias in selection of patients and data collection as well as to perform a fair data analysis and presentation. Although we report on a series of 156 consecutive hostile aortic neck EVAR cases, we still have the limitation of a relatively small number of patients with even lower adverse event rates. On the other hand, it is a series with greater possible homogeneity in treatment and follow-up protocol, and this strengthens our conclusions for the value of lastgeneration endografts with suprarenal fixation in the "real world" of EVAR under hostile aortic neck conditions. However, the design of a multicenter and prospective study for assessment of last-generation endografts with suprarenal fixation is necessary to draw firm conclusions of the value of EVAR in patients with short and conical proximal aortic neck and potentially to re-evaluate the current IFU standards.
CONCLUSIONS
Our study suggests that a conical neck (reverse taper anatomy with gradual neck dilation >2 mm) is the single strongest predictor of proximal failure in cases with short (<15 mm) proximal aortic neck treated by standard EVAR. The concomitant presence, alone or in combination, of wide, angulated proximal aortic neck and thrombus or calcification seems not to play a significant role in adverse outcomes. In addition, current IFU standards of last-generation endografts with suprarenal fixation restrict applicability and reduce their potential use for standard EVAR in hostile neck conditions. However, pending results from larger multicenter and prospective studies, this off-label use must be offered cautiously and by vascular surgeons with experience in standard EVAR.
